All News

Data from 2024 are being used as a way to predict what changes may be on the way for 2025.

Mycophenolate mofetil oral suspension is the only FDA-approved ready-to-use liquid formulation.

The market is sensitive to both upstream and downstream pressures that impact drug pricing.

The specialty drug market has exploded, and will continue to grow across sectors such as oncology and neurology.

Researchers continue to report on the rise of syphilis in the US, with recent cases exhibiting rare symptoms in the eyes, ears, and brain.

In case you missed it, this week we had news about marijuana reclassification, the Change Healthcare cyberattack, declining wages among community pharmacists, and more.

Check out a recap of important pharmacy news you might’ve missed this week, dispensed in small doses.

Check out important updates from the FDA for the week of April 29.

A lack of clarity around certain provisions of the Inflation Reduction Act has presented challenges to payers.

Are you a Wookie with a mane to maintain or a scoundrel prone to nausea? You don’t have to traverse distant planets to find OTC recommendations that meet your needs—this guide has you covered.

A siloed approach to care can worsen patient outcomes, but collaboration between one health system specialty pharmacy and a manufacturer led to better patient care.

A review found that many guidelines that recommended pharmacogenetic testing were inconsistent between clinical associations.

Understanding the goals of each party is the first step to a successful collaboration.

Collaboration between health system specialty pharmacists and pharmaceutical manufacturers can benefit patients in the long run.

The rise of weight-loss drugs has overtaken the US prescription drug market and significantly increased spending from 2022 to 2023.

The current study highlights the potential benefit of incorporating continuous glucose monitor (CGM) data into eye care assessments for patients with type 1 diabetes (T1D).

Addressing requirements around FDA interchangeability designations can increase the adoption of biosimilar substitutions at the pharmacy level.

A recent bill introduced to Congress is intended to prevent product hopping, a practice that extends exclusivity and hinders the adoption of biosimilar therapies.

Distributors can help manufacturers create patient access programs that reduce costs, copays, and co-insurance.

One notable incentive includes the launch of biosimilars at both low- and high wholesale acquisition costs.

The organization has renewed its recommendation of Prescryptive Health’s artificial intelligence pricing system, stating it can help independent pharmacies stay competitive.

According to Michael Osso, president and chief executive officer of the Crohn’s & Colitis Foundation, “the flexibility of having multiple biosimilar formulations to choose from is important to support broader patient access to biologic medicine.”

In a testimony to the Senate Finance Committee, Andrew Witty discussed what led to the February Change Healthcare cyberattack and the organization’s response.

Pharmacists can help financial decision makers understand the value of biosimilar therapies.

Although the US Drug Enforcement Agency's (DEA) proposed reclassification of marijuana wouldn’t legalize the drug nationwide, it could shake up the current marijuana landscape.

Savings associated with biosimilar uptake are projected to reach $181 billion through 2027.

The role of health care specialty pharmacies has expanded.

Check out this list of our 10 most read stories from April 2024.